A 1-year controlled trial of acetyl-L-carnitine in early-onset AD

Neurology

Volumn 55, Issue 6, 2000, Pages 805-810

  Thal, L J ^a   Calvani, M ^b   Amato, A ^b   Carta, A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Sigma Tau Pharmaceuticals Inc   (United States)

^c Worldwide Clinical Trials   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; LEVACECARNINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ONSET AGE; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

EID: 0034718466     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.55.6.805     Document Type: Article

References (38)

1. The prevalence of malignancy of Alzheimer's disease
2. Estimated prevalence of Alzheimer's disease in the United States
3. Epidemiology of clinically diagnosed Alzheimer's disease
4. Age at onset of Alzheimer's disease: Relation to pattern of cognitive dysfunction and rate of decline
5. Clinical predictors of course for Alzheimer patients in a longitudinal study: A preliminary report
6. Comparison of rate of annual change of mental status scores in four independent studies of patients with Alzheimer's disease
7. Deterioration on the Blessed test in Alzheimer's disease: Longitudinal data and their implications for clinical trials and identification of subtypes
8. Physical basis of cognitive alterations in Alzheimer's disease: Synapse loss is the major correlate of cognitive impairment
9. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
10. Stimulation of oxidation of mitochondrial fatty acids and acetate by acetylcarnitine
11. Characteristics of function of, and deficiency of carnitine acetylcarnitine translocase
12. Uptake of acetyl-L-carnitine in the brain
13. Acetyl-L-carnitine as a precursor of acetylcholine
14. 1H/NMR spectroscopy
15. Action of acetyl-L-carnitine on different cerebral mitochondrial populations from hippocampus and striatum during aging
16. Levocarnitine acetyl affects synaptic transmission in aged rats
17. Transient nigral ubiquinone depletion after single MPTP administration in mice
18. Acetyl-L-carnitine enhances the response of PC12 cells to nerve growth factor
19. Treatment with acetyl-L-carnitine (ALCAR) elevates NGF levels in the CNS of aged rats
20. Active avoidance learning in old rats chronically treated with ALCAR
21. Long-term acetyl-L-carnitine treatment in Alzheimer's disease
22. Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease
23. A one-year multicenter placebo-controlled study of acetyl-L-carnitine in patients with Alzheimer's disease
24. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease
25. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician
26. Pathological verification of ischemic score in differentiation of dementia
27. A new rating scale for Alzheimer's disease
28. A new clinical scale for staging of dementia
29. Assessment of older people: Self-maintaining and instrumental activities of daily living
30. Clinical global impressions
31. Rank analysis of covariance
32. Rates of change of common measures of impairment in senile dementia of the Alzheimer's type
33. A longitudinal study of Alzheimer's disease: Measurement, rate, and predictors of cognitive deterioration
34. Acetyl-L-carnitine in the treatment of mildly demented elderly patients
35. Acetyl-L-carnitine: Its role in neuronal metabolism
36. Age-dependent loss of NMDA receptors in hippocampus, striatum, and frontal cortex of the rat: Prevention by acetyl-L-carnitine